Berlin-based Siemens Healthineers has closed its $1.1bn acquisition of US-based Corindus Vascular Robotics.

Corindus manufactures robotic systems for minimally invasive procedures, while Siemens’ products use quality imaging before and during medical interventions to make minimally invasive treatment possible.

At a shareholders’ meeting held last week, 87.5% of its stockholders approved the acquisition.

The deal had earlier gained approval from the regulatory authorities.

Siemens Healthineers CEO Bernd Montag said: “With the completion of the acquisition, we are opening up a new field for our Advanced Therapies business, tapping into adjacent growth markets with great potential for the future. We are taking an important step forward in the upgrading phase of our 2025 strategy.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Following the completion of the deal, Massachusetts-based Corindus has become a part of the Advanced Therapies reporting segment.

Corindus former president and CEO Mark J Toland said: “The combination of Siemens Healthineers’ strong medical technology portfolio with its digital platforms and solutions, together with Corindus’ precision robotics platform, has the potential to transform healthcare delivery so that, together, we can provide better care at lower cost.”

Toland will continue to be responsible for managing Corindus Vascular Robotics within Siemens Healthineers.

Following the acquisition, Siemens’ role in image-based minimally invasive procedures will now be complemented by robotic-assisted precision medicine.

This acquisition expands Siemens’ Advanced Therapies business, combining its cardiovascular and neuro-interventional therapy systems with Corindus’s technology for image-based minimally invasive therapies.

In August, Siemens Healthineers had signed a definitive agreement to acquire Corindus Vascular Robotics for a deal valued at $4.28 per share in cash or $1.1bn in total.